4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$10.79 -0.50 (-4.43%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$11.04 +0.25 (+2.27%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FDMT vs. XNCR, ZLAB, NAMS, RCUS, and CLDX

Should you buy 4D Molecular Therapeutics stock or one of its competitors? 4D Molecular Therapeutics's main competitors and comparable companies include Xencor (XNCR), Zai Lab (ZLAB), NewAmsterdam Pharma (NAMS), Arcus Biosciences (RCUS), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4D Molecular Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 7 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat 4D Molecular Therapeutics' score of -0.14 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Xencor has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xencor has higher revenue and earnings than 4D Molecular Therapeutics. Xencor is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M20.62-$91.92M-$1.59N/A
4D Molecular Therapeutics$85.21M7.14-$140.11M-$2.70N/A

Xencor has a net margin of -58.79% compared to 4D Molecular Therapeutics' net margin of -208.57%. Xencor's return on equity of -21.28% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-58.79% -21.28% -15.17%
4D Molecular Therapeutics -208.57%-47.06%-40.05%

Xencor presently has a consensus price target of $42.22, suggesting a potential upside of 22.38%. 4D Molecular Therapeutics has a consensus price target of $30.22, suggesting a potential upside of 180.09%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
4D Molecular Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Xencor beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Zai Lab had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 13 mentions for Zai Lab and 10 mentions for 4D Molecular Therapeutics. Zai Lab's average media sentiment score of 0.75 beat 4D Molecular Therapeutics' score of -0.14 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

4D Molecular Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M6.40-$175.54M-$1.79N/A
4D Molecular Therapeutics$85.21M7.14-$140.11M-$2.70N/A

Zai Lab has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market.

Zai Lab has a net margin of -44.91% compared to 4D Molecular Therapeutics' net margin of -208.57%. Zai Lab's return on equity of -31.15% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-44.91% -31.15% -18.17%
4D Molecular Therapeutics -208.57%-47.06%-40.05%

Zai Lab presently has a consensus price target of $37.25, indicating a potential upside of 58.31%. 4D Molecular Therapeutics has a consensus price target of $30.22, indicating a potential upside of 180.09%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
4D Molecular Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Zai Lab and 4D Molecular Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to NewAmsterdam Pharma?

4D Molecular Therapeutics (NASDAQ:FDMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

4D Molecular Therapeutics has a net margin of -208.57% compared to NewAmsterdam Pharma's net margin of -789.95%. NewAmsterdam Pharma's return on equity of -31.39% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-208.57% -47.06% -40.05%
NewAmsterdam Pharma -789.95%-31.39%-28.32%

4D Molecular Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 8 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.32 beat 4D Molecular Therapeutics' score of -0.14 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
NewAmsterdam Pharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

4D Molecular Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$85.21M7.14-$140.11M-$2.70N/A
NewAmsterdam Pharma$22.50M103.35-$203.82M-$1.69N/A

4D Molecular Therapeutics currently has a consensus target price of $30.22, suggesting a potential upside of 180.09%. NewAmsterdam Pharma has a consensus target price of $49.82, suggesting a potential upside of 156.93%. Given 4D Molecular Therapeutics' higher probable upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

4D Molecular Therapeutics beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Arcus Biosciences?

4D Molecular Therapeutics (NASDAQ:FDMT) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Arcus Biosciences. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 2 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.26 beat 4D Molecular Therapeutics' score of -0.14 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Arcus Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

4D Molecular Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

4D Molecular Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$85.21M7.14-$140.11M-$2.70N/A
Arcus Biosciences$247M9.57-$353M-$3.63N/A

4D Molecular Therapeutics presently has a consensus price target of $30.22, suggesting a potential upside of 180.09%. Arcus Biosciences has a consensus price target of $39.36, suggesting a potential upside of 139.85%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

4D Molecular Therapeutics has a net margin of -208.57% compared to Arcus Biosciences' net margin of -453.00%. 4D Molecular Therapeutics' return on equity of -47.06% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-208.57% -47.06% -40.05%
Arcus Biosciences -453.00%-91.65%-46.72%

Summary

4D Molecular Therapeutics beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat 4D Molecular Therapeutics' score of -0.14 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Celldex Therapeutics currently has a consensus price target of $64.08, suggesting a potential upside of 128.54%. 4D Molecular Therapeutics has a consensus price target of $30.22, suggesting a potential upside of 180.09%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
4D Molecular Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$1.54M1,430.40-$258.76M-$4.30N/A
4D Molecular Therapeutics$85.21M7.14-$140.11M-$2.70N/A

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -208.57%. 4D Molecular Therapeutics' return on equity of -47.06% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
4D Molecular Therapeutics -208.57%-47.06%-40.05%

Summary

4D Molecular Therapeutics beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$636.52M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-4.0026.6634.2628.24
Price / Sales7.1415.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book1.804.184.463.72
Net Income-$140.11M-$24.15M$3.52B$393.10M
7 Day Performance-16.94%-7.78%-5.92%-5.76%
1 Month Performance-11.12%-5.96%-4.58%-7.14%
1 Year Performance6.94%-8.08%-1.93%-7.46%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.8858 of 5 stars
$10.79
-4.4%
$30.22
+180.1%
-1.5%$636.52M$85.21MN/A196
XNCR
Xencor
2.638 of 5 stars
$38.59
+7.9%
$42.22
+9.4%
+120.9%$2.60B$125.58MN/A260
ZLAB
Zai Lab
3.6176 of 5 stars
$26.86
+5.4%
$37.25
+38.7%
+12.5%$2.59B$460.16MN/A1,784
NAMS
NewAmsterdam Pharma
3.3622 of 5 stars
$19.00
+0.5%
$48.70
+156.3%
-49.7%$2.50B$22.50MN/A100
RCUS
Arcus Biosciences
2.8994 of 5 stars
$18.90
+3.4%
$39.36
+108.3%
-17.9%$2.46B$247MN/A601

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners